Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis
Open Access
- 1 August 2017
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 26 (8) , 1328-1336
Abstract
Background: Several studies suggest that test characteristics for the fecal immunochemical test (FIT) differ by gender, triggering a debate on whether men and women should be screened differently. We used the microsimulation model MISCAN-Colon to evaluate whether screening stratified by gender is cost-effective. Methods: We estimated gender-specific FIT characteristics based on first-round positivity and detection rates observed in a FIT screening pilot (CORERO-1). Subsequently, we used the model to estimate harms, benefits, and costs of 480 gender-specific FIT screening strategies and compared them with uniform screening. Results: Biennial FIT screening from ages 50 to 75 was less effective in women than men [35.7 vs. 49.0 quality-adjusted life years (QALY) gained, respectively] at higher costs (€42,161 vs. −€5,471, respectively). However, the incremental QALYs gained and costs of annual screening compared with biennial screening were more similar for both genders (8.7 QALYs gained and €26,394 for women vs. 6.7 QALYs gained and €20,863 for men). Considering all evaluated screening strategies, optimal gender-based screening yielded at most 7% more QALYs gained than optimal uniform screening and even resulted in equal costs and QALYs gained from a willingness-to-pay threshold of €1,300. Conclusions: FIT screening is less effective in women, but the incremental cost-effectiveness is similar in men and women. Consequently, screening stratified by gender is not more cost-effective than uniform FIT screening. Impact: Our conclusions support the current policy of uniform FIT screening. Cancer Epidemiol Biomarkers Prev; 26(8); 1328–36. ©2017 AACR.Keywords
All Related Versions
This publication has 32 references indexed in Scilit:
- Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trialThe Lancet Oncology, 2012
- Cost-effectiveness of Colorectal Cancer ScreeningEpidemiologic Reviews, 2011
- Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trialThe Lancet, 2010
- Effect of Rising Chemotherapy Costs on the Cost Savings of Colorectal Cancer ScreeningJNCI: Journal of the National Cancer Institute, 2009
- Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopyGut, 2009
- Individualizing colonoscopy screening by sex and raceGastrointestinal Endoscopy, 2009
- A novel hypothesis on the sensitivity of the fecal occult blood testCancer, 2009
- The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screeningBritish Journal of Cancer, 2009
- Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levelsBritish Journal of Cancer, 2009
- Guidelines for Pharmacoeconomic StudiesPharmacoEconomics, 1997